Neogenomics (NEO) Operating Expenses (2010 - 2026)

Neogenomics (NEO) has 17 years of Operating Expenses data on file, last reported at $101.6 million in Q2 2026.

• Quarterly Operating Expenses fell 18.61% year-over-year to $101.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $405.0 million (down 3.05% YoY) and the FY2025 annual result came in at $430.2 million, up 12.55% from the prior year.
• Operating Expenses improved to $101.6 million in Q2 2026, from $99.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $124.9 million in Q2 2025 to a low of $83.2 million in Q4 2022.
• A 5-year average of $95.1 million and a median of $95.0 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 59.24% — and 2026, when it fell 18.61%.
• Tracing NEO's Operating Expenses over 5 years: stood at $83.2 million in 2022, then increased by 3.55% to $86.2 million in 2023, then grew by 11.02% to $95.7 million in 2024, then advanced by 1.15% to $96.8 million in 2025, then grew by 5.06% to $101.6 million in 2026.
• The last three Operating Expenses figures came in at $101.6 million (Q2 2026), $99.1 million (Q1 2026), and $96.8 million (Q4 2025), per Business Quant data.